Alumis Inc. (NASDAQ:ALMS - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Alumis in a research report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($1.46) per share for the quarter. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share.
Other equities research analysts have also issued reports about the stock. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Alumis in a report on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Alumis in a research note on Thursday, March 20th. Finally, Oppenheimer began coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an "outperform" rating and a $32.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Alumis has an average rating of "Buy" and an average target price of $26.00.
Read Our Latest Stock Analysis on ALMS
Alumis Stock Performance
Shares of NASDAQ:ALMS traded up $0.94 during trading on Tuesday, hitting $5.64. 1,623,981 shares of the company's stock were exchanged, compared to its average volume of 285,901. The business's 50-day simple moving average is $5.39 and its 200 day simple moving average is $8.31. Alumis has a 52-week low of $3.18 and a 52-week high of $13.53.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in shares of Alumis in the 3rd quarter valued at approximately $27,000. Wells Fargo & Company MN increased its stake in Alumis by 77.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock worth $69,000 after buying an additional 3,823 shares during the period. Northern Trust Corp lifted its holdings in Alumis by 4.3% during the 4th quarter. Northern Trust Corp now owns 111,326 shares of the company's stock valued at $875,000 after buying an additional 4,587 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Alumis by 4.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company's stock valued at $891,000 after buying an additional 4,808 shares during the period. Finally, Barclays PLC increased its position in shares of Alumis by 33.9% during the fourth quarter. Barclays PLC now owns 24,581 shares of the company's stock worth $193,000 after acquiring an additional 6,221 shares during the period.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Further Reading
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
